Neuroactive steroid for the treatment of mild cognitive impairment associated with parkinson's disease
AssigneeSage Therapeutics, Inc.
InventorsJames J. Doherty, Michael C. Quirk, Aaron Michael Koenig, Jason Karl Johannesen
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for improving working memory and/or executive function in a subject suffering from Parkinson's Disease, comprising administering to the subject a compound having the formula.
Claims93
A method of treating Mild Cognitive Impairment (MCI) associated with Parkinson's Disease in a subject, comprising administering to the subject a compound having the formula of Compound 1
- or a pharmaceutically acceptable salt thereof.
A method of improving executive function in a subject having Mild Cognitive Impairment (MCI) associated with Parkinson's Disease, the method comprising administering to the subject a compound having the formula of Compound 1
- or a pharmaceutically acceptable salt thereof.
A method of improving working memory in a subject having Mild Cognitive Impairment (MCI) associated with Parkinson's Disease, the method comprising administering to the subject a compound having the formula of Compound 1
- or a pharmaceutically acceptable salt thereof.
A method of improving learning in a subject having Mild Cognitive Impairment (MCI) associated with Parkinson's Disease, the method comprising administering to the subject a compound having the formula of Compound 1
- or a pharmaceutically acceptable salt thereof.
A method of improving learning and working memory in a subject having Mild Cognitive Impairment (MCI) associated with Parkinson's Disease, the method comprising administering to the subject a compound having the formula of Compound 1
- or a pharmaceutically acceptable salt thereof.
Use of Compound 1
- or a pharmaceutically acceptable salt thereof,
- for the manufacture of a medicament for treating Mild Cognitive Impairment (MCI) associated with Parkinson's Disease in a subject.
Use of Compound 1
- or a pharmaceutically acceptable salt thereof,
- for the manufacture of a medicament for improving executive function in a subject having Mild Cognitive Impairment (MCI) associated with Parkinson's Disease.
Use of Compound 1
- or a pharmaceutically acceptable salt thereof,
- for the manufacture of a medicament for improving working memory in a subject having Mild Cognitive Impairment (MCI) associated with Parkinson's Disease.
Use of Compound 1
- or a pharmaceutically acceptable salt thereof,
- for the manufacture of a medicament for improving learning in a subject having Mild Cognitive Impairment (MCI) associated with Parkinson's Disease.
Use of Compound 1
- or a pharmaceutically acceptable salt thereof,
- for the manufacture of a medicament for improving learning and working memory in a subject having Mild Cognitive Impairment (MCI) associated with Parkinson's Disease.
A compound having the structure of Compound 1
- or a pharmaceutically acceptable salt thereof,
- for use in treating Mild Cognitive Impairment (MCI) associated with Parkinson's Disease in a subject.
A compound having the structure of Compound 1
- or a pharmaceutically acceptable salt thereof,
- for use in improving executive function in a subject having Mild Cognitive Impairment (MCI) associated with Parkinson's Disease.
A compound having the structure of Compound 1
- or a pharmaceutically acceptable salt thereof,
- for use in improving working memory in a subject having Mild Cognitive Impairment (MCI) associated with Parkinson's Disease.
A compound having the structure of Compound 1
- or a pharmaceutically acceptable salt thereof,
- for use in improving learning in a subject having Mild Cognitive Impairment (MCI) associated with Parkinson's Disease.
A compound having the structure of Compound 1
- or a pharmaceutically acceptable salt thereof,
- for use in improving learning and working memory in a subject having Mild Cognitive Impairment (MCI) associated with Parkinson's Disease.
Dependencies are inferred from the claim text.